SEC Comment Letter for Generation Bio Co. (GBIO) (CIK 0001733294) — Dec 23, 2020
Generation Bio Co. (GBIO) (CIK 0001733294)
Date: Dec. 23, 2020 · CIK: 0001733294 · Accession: 0000000000-20-012386
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo December 23, 2020 Geoff McDonough, M.D. President and Chief Executive Officer Generation Bio Co. 301 Binney Street Cambridge, MA 02142 Re:Generation Bio Co. Draft Registration Statement on Form S-1 Submitted December 21, 2020 CIK No. 0001733294 Dear Dr. McDonough: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stuart Falber, Esq.
Show Raw Text
United States securities and exchange commission logo
December 23, 2020
Geoff McDonough, M.D.
President and Chief Executive Officer
Generation Bio Co.
301 Binney Street
Cambridge, MA 02142
Re:Generation Bio Co.
Draft Registration Statement on Form S-1
Submitted December 21, 2020
CIK No. 0001733294
Dear Dr. McDonough:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stuart Falber, Esq.